|
WO2007130950A2
|
|
Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
|
|
CN101495123A
|
|
Methods and compositions for increasing the safety and efficacy of albumin-binding drugs
|
|
WO2005041895A2
|
|
Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
|
|
US2007253945A1
|
|
Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
|
|
WO2004108890A2
|
|
Dilute methanol -or ethanol- induced production of polypeptides in microorganisms
|
|
EP1627323A2
|
|
Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
|
|
US7179838B2
|
|
Coumarin analog compounds for safer anticoagulant treatment
|
|
AU2003228962A1
|
|
Ferritin fusion proteins for use in vaccines and other applications
|
|
EP1488011A2
|
|
Method of isolating binding peptides from a combinatorial phage display library and peptides produced thereby
|
|
AU2003225630A1
|
|
Atomic structure of the hemalbumin complex and its use in designing therapeutic compounds
|
|
WO03050522A1
|
|
Method and apparatus for use of thermally switching proteins in sensing and detecting devices
|
|
WO02102830A1
|
|
Human albumin animal models for drug evaluation, toxicology and immunogenicity studies
|
|
WO02074246A2
|
|
Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
|
|
US6787636B1
|
|
Modified serum albumin with reduced affinity for nickel and copper
|
|
AU1618499A
|
|
Oxygen-transporting albumin-based blood replacement composition and blood volumeexpander
|
